Rejected from PLOS Medicine? The 7 Best Journals to Submit Next

Source: Clarivate JCR 2024, PLOS, BioMed Central, Elsevier/Lancet, and BMJ journal pages and guides for authors (accessed June 2026). APCs are list prices excluding tax and may be waived or reduced.

1. PLOS ONE. This is the in-portfolio destination for technically sound work that did not clear the flagship's significance bar. PLOS ONE judges on methodological rigor rather than perceived importance, so a study rejected for "not general-interest enough" often fits cleanly. The transfer carries your files (and referee reports, if relevant), which removes most of the resubmission overhead.

2. BMC Medicine. The strongest selective open-access general-medicine alternative for a paper with genuine clinical, translational, public-health, or policy relevance. It rewards work that connects the result to a downstream decision and runs a relatively fast first-decision cycle for its tier.

3. eClinicalMedicine. Part of Lancet Discovery Science, this venue is built for clinically actionable research, the same practice-change framing PLOS Medicine screens for. If your reviewers liked the significance but the paper missed on fit or generalizability, this is a strong lateral move rather than a step down.

4. PLOS Global Public Health. The right home when the manuscript's real contribution is population health, health equity, or health-systems performance, especially in global or low-resource settings. It is the natural in-portfolio transfer for work whose significance is public-health rather than bedside-clinical.

5. BMJ Open. A broad, high-volume open-access journal that publishes on a sound-science threshold without a novelty or general-interest bar. Reach for it when the work is rigorous and reportable but unlikely to clear a significance screen at a flagship, and you want a defensible, indexed home reasonably fast.

6. The BMJ. Only if the work is a major general-medicine advance with clear practice or policy impact and you are willing to face another highly selective screen. It is a re-aim-high option, not a step down, and it suits papers where the significance was never the problem.

7. Annals of Internal Medicine. The aspirational internal-medicine target for broadly important clinical research. The bar is correspondingly high, so reach for it only when the contribution is squarely internal medicine and the practice relevance is unambiguous.

PLOS runs an in-portfolio transfer: a rejected original-research submission, handled in the journal's Editorial Manager portal at Editorial Manager submission portal, can be moved to another PLOS journal at your request rather than resubmitted from scratch, with referee reports carried over if relevant. The natural landing spots are PLOS ONE (significance-agnostic, rigor-based) and PLOS Global Public Health (population and health-systems framing). You can accept the transfer, decline it, or ignore it and submit elsewhere manually.

A transfer offer is a routing suggestion, not a quality endorsement, so treat the destination as you would any other target. Outside PLOS, BMC Medicine and the broader BioMed Central portfolio also operate manuscript-transfer routes you can initiate.

Practical ladder by rejection reason:

• Desk-rejected for significance (the result is real but does not change practice or policy)? Step down to PLOS ONE or BMC Medicine, or re-aim laterally at eClinicalMedicine if the practice relevance is genuine. The first choice is usually the in-portfolio PLOS ONE transfer.

• Rejected for limited generalizability but sound methodology? This is the classic step-down or transfer case.

PLOS ONE or BMJ Open accepts rigorous work without the external-validity bar; do not waste the effort re-aiming high until the generalizability argument is stronger.

• Rejected after review for an incomplete reporting checklist, weak controls, or a missing data-availability statement? Fix it before resubmitting anywhere. Every serious medical journal in this list enforces CONSORT, PRISMA, or STROBE and a data-availability statement. Carry the corrected checklist and statement into the transfer or the manual resubmission.

In our pre-submission review work with PLOS Medicine manuscripts, the rejections we see most often cluster into four named patterns. Each is journal-specific and testable against your own manuscript, which is what makes them worth checking before you resubmit anywhere.

The missing practice-change claim. Across our PLOS Medicine pre-submission reviews, the single most common desk-rejection trigger is a well-powered study that never states what clinicians or policymakers should do differently. The abstract and introduction report a significant association or effect, but no sentence connects it to a guideline, a treatment decision, or a health-systems practice.

PLOS Medicine explicitly screens for "clear implications for patient care, public policy or clinical research agendas," so reviewers and staff editors expect the consequence built into the framing, not added as a speculative line in the Discussion. The fix is concrete: state, in the abstract, the specific decision your evidence should change. Without it, a clean methods section reads as a specialist paper.

This is testable: read your own abstract and ask whether a practicing clinician could name the action your result implies.

Single-center or narrow-population work framed as general-interest. A second recurring pattern in the PLOS Medicine manuscripts we review is a single-site cohort or one-population result presented as broadly applicable, with no discussion of external validity. The journal weighs generalizability and cross-disciplinary interest heavily, and reviewers consistently flag the gap between the claim and the setting.

The fix is either an honest generalizability paragraph in the Discussion that names where the result should and should not travel, or a reframing of the contribution as a hypothesis-generating finding for a more specialist venue.

Incomplete reporting checklists and methodology gaps. We see clinical trials submitted without a complete CONSORT checklist, systematic reviews without PRISMA, and observational studies without STROBE, where the checklist is either absent or filled in with page numbers but no excerpted manuscript text.

PLOS Medicine asks authors to complete the appropriate reporting checklist with enough text to show how each item was met, and a thin or missing checklist signals an evidence package that is not first-screen-ready. Reviewers also reject when statistical analysis does not match the study design or when the sample size is unjustified. Check that every applicable checklist is complete and that every headline claim has a matched control and an appropriate statistical test.

Missing data-availability statement and transparency drift. The fourth pattern is a manuscript with no data-availability statement, or one that points to data "available on request" rather than a public repository. PLOS requires that the data underlying the findings be deposited in an appropriate repository, at least as open as CC BY, unless already in the article. A submission that cannot satisfy this transparency standard is filtered fast, regardless of the strength of the result.

Read your own submission and confirm there is a concrete, repository-backed data-availability statement before you resubmit, because the next medical journal on this list will check for it too.

Don't just resubmit the same file down the ladder. The fastest way to collect a second rejection is to send an unrevised manuscript to a journal that screens for the same thing PLOS Medicine did, and some manuscripts need real work, not a faster next submission. A desk rejection for significance or scope is a routing problem you can fix by choosing the right journal and reframing the abstract.

A post-review rejection for an incomplete CONSORT, PRISMA, or STROBE checklist, weak controls, or a missing data-availability statement is a substance problem, and the same concerns will reappear at any serious venue. Be honest about which one you got.

Two cases call for real work before resubmitting, not a faster next submission. First, if reviewers questioned whether the result is clinically or policy-meaningful, the manuscript needs the practice-change claim and the generalizability paragraph it was missing. Second, if the reporting checklist, controls, or statistics were challenged, new analysis (and sometimes the full, text-excerpted checklist) is the only fix.

Appealing is rarely worth it: a significance or generalizability rejection is an editorial judgment, not a factual error, and the appeal queue is slower than a clean resubmission to a better-fit journal.